Flow cytometric analysis of C57BL/6 mouse splenocytes treated with 500ng/ml LPS for 3 days, labelling CD86/B7-2 antibody at 1/2000 (0.1 μg) dilution (Right) compared with a Mouse monoclonal IgG isotype control (Left). Then cells were stained with CD19 - PE/Cy7 separately. Goat Anti - Mouse IgG Alexa Fluor® 647 was used as the secondary antibody. Gated on total viable cells.
Product Details
Product Details
Product Specification
Host | Rat |
Antigen | CD86/B7-2 |
Synonyms | T-lymphocyte activation antigen CD86, Activation B7-2 antigen, B70, BU63, CTLA-4 counter-receptor B7.2, FUN-1 |
Location | Cell membrane |
Accession | P42081 |
Clone Number | S-R434 |
Antibody Type | Mouse mAb |
Isotype | IgG2a,k |
Application | FCM |
Reactivity | Ms |
Purification | Protein G |
Concentration | 2 mg/ml |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
application | dilution | species |
FCM | 1:2000 |
Background
CD86, also known as B7-2, is a crucial protein molecule in the immune system, belonging to the B7 protein family. This family comprises various costimulatory molecules that are essential for T-cell activation, proliferation, and the exertion of effector functions. CD86 provides the second signal (costimulatory signal) for T-cell activation by binding to the CD28 receptor on T-cells. This signal is necessary for the full activation and differentiation of T-cells into effector T-cells (e.g., Th1, Th2) or memory T-cells. CD86 also exerts a negative regulatory role through its interaction with the CTLA-4 receptor on T-cells. CTLA-4 has a higher affinity for CD86 than CD28, allowing it to competitively bind to CD86 during the later stages of T-cell activation, thereby inhibiting further T-cell activation and preventing excessive immune responses. CD86 also exerts a negative regulatory role through its interaction with the CTLA-4 receptor on T-cells. CTLA-4 has a higher affinity for CD86 than CD28, allowing it to competitively bind to CD86 during the later stages of T-cell activation, thereby inhibiting further T-cell activation and preventing excessive immune responses.
Picture
Picture
FC
